SINGAPORE and BOULDER, Colo., Nov. 08, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that Singapore-based Molecular Genomics, a Genomax Technologies company, will be the first site in Asia to offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers.
“We are honored to be able to partner with SomaLogic to bring the industry leading SomaScan Platform to the region,” said Genomax Technologies and Molecular Genomics Chief Executive Officer Mr. Wong Lin Sheng. “Together with our existing genomics and single-cell analysis services, we will be able to provide an unparalleled multi-omics service platform to customers in Southeast Asia and beyond.”
Molecular Genomics is accelerating biodiscovery in Southeast Asia by combining the power of SomaLogic’s proteomics platform, the largest currently available, with next-generation sequencing and microarray-based genomics analysis. The company has served the Southeast Asia biotech community for 11 years.
“Southeast Asia is an incredibly important and rapidly growing market for translational work in clinical research and life sciences,” said SomaLogic Chief Executive Officer Roy Smythe, M.D. “We have a number of exciting projects going on in Asia and we are pleased to be working with Molecular Genomics as part of the expansion and distribution of our proteomics technology in this region.”
SomaLogic’s proprietary SomaScan Platform was designed to be a universal platform that can be applied across research and discovery, translational research and biopharmaceutical development, and clinical applications. SomaLogic can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample. The company has run more than 550,000 samples to date.
About SomaLogic
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.
Forward Looking Statements Disclaimer
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Media Contact
Emilia Costales
720-798-5054
ecostales@somalogic.com
Investor Contacts
Marissa Bych
Gilmartin Group LLC
Marissa@gilmartinir.com
